Eisai prevails against Teva, Dr. Reddy's; Ranbaxy cleared in U.K. fraud case;

> A federal circuit court upheld Eisai's patent on its acid reflux drug Aciphex, once again staving off challenges by Teva Pharmaceuticals and Dr. Reddy's Laboratories. Release

> The U.K. subsidiary of Ranbaxy Laboratories was cleared in a price-fixing fraud case, the company said Tuesday. Report

> India's Bilcare and U.S.-based MeadWestVaco together acquired the pharmaceutical packaging company International Labs for an undisclosed amount. Report

> Roche said Tuesday it will buy U.S. gene therapy company Mirus Bio Corp. for $125 million. Report

> Boehringer Ingelheim and Astellas Pharma have filed suit against Impax, alleging that its generic version of Flomax infringes on their patents. Report

> The latest venture capital numbers for the second quarter are in, and biotech is down--along with the rest of the tech crowd. Report

> Ireland's Elan is considering selling its development and manufacturing division for around $1.5 billion. Report

> A variety of public and private venture groups in China have created a loosely structured association that will back early-stage biotech ventures. Report

> Seattle-based Cell Therapeutics is sending out an SOS signal to investors. "We have an immediate need to raise additional capital in the next thirty days in order to meet our operation needs," the company said in SEC documents. Report

> Marks & Clerk, a patent firm, surveyed some 500 biotech executives in the U.S. and U.K. and detected a distinct note of alarm over investors' dwindling appetite for the kind of risk presented by drug development. Report

> Cougar Biotechnology's early-stage prostate cancer therapy is being hailed by researchers for significantly improving outcomes for 250 refractive men who participated in a clinical trial. Report

> Magnetic nanoparticles have been used to ‘drag' cancer cells out of the bodies of mice. Scientists at Georgia Tech coated the nanoparticles with a targeting molecule that caused them to bond to the cancer cells. Report

And Finally ... Why do cancer patients sometimes develop a sudden resistance to drugs that had been working? Report

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.